Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-release levetiracetam add-on therapy for refractory focal-onset epilepsy
2024-514499-42-00Phase 3Authorised
- Sponsor
- Neuraxpharm
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of levetiracetam in Focal Onset Epilepsy (3 arms), sponsored by Neuraxpharm. Primary endpoint: Focal-onset seizure frequency per week. Planned start Mar 2025; status: authorised.
02
Drugs
levetiracetam
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on 2024-514499-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514499-42-00.